Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase by Capelle, C.I. (Carine) van et al.
International Journal of Cardiology xxx (2018) xxx–xxx
IJCA-26758; No of Pages 7
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdCardiac outcome in classic infantile Pompe disease after 13 years of
treatment with recombinant human acid alpha-glucosidaseCarine I. van Capelle a,1,2, Esther Poelman a,1,2, Ingrid M. Frohn-Mulder b,1, Laurens P. Koopman b,1,
Johanna M.P. van den Hout a,1, Luc Régal c,1, Bjorn Cools d,1, Wim A. Helbing b,1, Ans T. van der Ploeg a,⁎,1
a Pompe Center and Center for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
b Department of Pediatrics, Division of Pediatric Cardiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
c Center of Human Genetics, Laboratory of Biochemical Neuroendocrinology, KU Leuven, Belgium
d Pediatric Cardiology, University Hospitals Leuven, Belgium⁎ Corresponding author at: Center for Lysosomal and M
University Medical Center, P.O. Box 2060, 3000 CB Rotterd
E-mail address: a.vanderploeg@erasmusmc.nl (A.T. va
1 This author takes responsibility for all aspects of the r
of the data presented and their discussed interpretation.
2 Equal contribution.
https://doi.org/10.1016/j.ijcard.2018.07.091
0167-5273/© 2018 The Authors. Published by Elsevier B.V
Please cite this article as: C.I. van Capelle, et
human acid alpha-glucosidase, Int J Cardiol (a b s t r a c ta r t i c l e i n f oArticle history:
Received 10 January 2018
Received in revised form 4 July 2018
Accepted 18 July 2018
Available online xxxxBackground: Cardiac failure is themain cause of death in untreated classic infantile Pompe disease, an inheritable
metabolic myopathy characterized by progressive hypertrophic cardiomyopathy. Since the introduction of
enzyme replacement therapy (ERT), survival has increased signiﬁcantly due to reduced cardiac hypertrophy
and improved cardiac function. However, little is known about ERT's long-term effects on the heart.
Methods: Fourteen patients were included in this prospective study. Cardiac dimensions, function, conduction
and rhythm disturbances were evaluated at baseline and at regular intervals thereafter.
Results: Treatment duration ranged from 1.1 to 13.9 years (median 4.8 years). At baseline, all patients had
increased left ventricular mass index (LVMI) (median LVMI 226 g/m2, range 98 to 599 g/m2, Z-score median 7,
range 2.4–12.4). During the ﬁrst four weeks, LVMI continued to increase in six patients. Normalization of LVMI
was observed in 13 patients (median 30 weeks; range 3 to 660 weeks). After clinical deterioration, LVMI
increased again slightly in one patient. At baseline, PR interval was shortened in all patients; it normalized in
only three. A delta-wave pattern on ECG was seen in six patients and resulted in documented periods of
supraventricular tachycardias (SVTs) in three patients, two of whom required medication and/or ablation. One
patient had severe bradycardia (35 beats/min).
Conclusion: This study shows that ERT signiﬁcantly reduced LVMI, and sustained this effect over a period of
13.9 years. The risk for rhythm disturbances remains. Regular cardiac evaluations should be continued, also
after initially good response to ERT.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Tachyarrhythmia1. Introduction
Before the introduction of enzyme replacement therapy (ERT),
cardiac failure was the main cause of death in patients with the classic
infantile form of Pompe disease (OMIM 232300), a lysosomal storage
disorder caused by deﬁciency of the enzyme acid alpha-glucosidase
(EC 3.2.1.20). A hallmark of the disease is the progressive accumulation
of glycogen, predominantly in skeletal and cardiac muscle, but also in
various other tissues throughout the body. Pompe disease presents as
a spectrum of clinical phenotypes, with the severest classic-infantile
form leading to complete deﬁciency of alpha-glucosidase. Patients
presentwith progressive generalizedmyopathy and cardiac hypertrophy.etabolic Diseases, Erasmus MC
am, The Netherlands.
n der Ploeg).
eliability and freedom from bias
. This is an open access article under
al., Cardiac outcome in classic
2018), https://doi.org/10.101Motor milestones are not achieved, and patients rarely survive beyond
one year of age. Cardiac failure is the main cause of death [1–4].
Since the introduction of ERT with recombinant human alpha-
glucosidase (rhGAA, alglucosidase alfa), survival has improved sig-
niﬁcantly, due mainly to reduced cardiac hypertrophy and improved
cardiac function [5–9]. However, little is known about the long-term
effects of ERT on the heart. The present report describes the effects of
ERT on cardiac size, cardiac function, and conduction pattern in
fourteen classic-infantile Pompe patients over a treatment period
up of 13.9 years.2. Material and methods
2.1. Patients
This study is part of an ongoing prospective clinical study investigating the safety and
efﬁcacy of ERT in classic-infantile Pompe patients. Classic-infantile Pompe disease was
conﬁrmedby profound deﬁciency ofα-glucosidase inﬁbroblasts (b1%),mutation analysis,
and the presence of hypertrophic cardiomyopathy. For this study of long-term effects,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2 C.I. van Capelle et al. / International Journal of Cardiology xxx (2018) xxx–xxxwe only included patients who had been receiving ERT for at least 12 months. ERT doses
ranged from 20 mg/kg every other week to 40 mg/kg weekly.
During the study period ﬁve additional patients were diagnosed. Four did not start
ERT because of poor respiratory and/or motor condition or because parents decided not
to start ERT. The ages of these patients at time of diagnosis ranged from 2.6–4.6 months.
LVMI ranged from 171 to 523 g/m2 at time of diagnosis, and were in the same range as
the study cohort, none of these patients was ventilator dependent. All untreated patients
died before the age of one year.
2.2. Study design
The study was performed at Erasmus MC University Medical Center - Sophia
Children's Hospital Rotterdam (Netherlands), and was approved by the Institutional
Review Board. Written informed consent was obtained from parents or legal guardians.
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki
as reﬂected in a priori approval by the Institutional Review Board. Standardized assess-
ments were performed before the start of ERT and every three months thereafter.
2.3. Echocardiography
Conventional echocardiography with trans-thoracic M-Mode, two-dimensional
echocardiography and conventional echo-Doppler measurements was performed by an
experienced sonographer (JP) using a Philips iE33 Echocardiography System (Philips
Medical Systems, Andover, MA, USA). Recordings were made at baseline and at regular
intervals thereafter according to the recommendations of the American Society of
Echocardiography [10]. The following parameters were documented: left ventricular
internal cavity dimension in diastole (LVIDd), inter-ventricular septum thickness in
diastole (IVSd), left ventricular posterior wall thickness in diastole (LVPWd), and left
and right ventricular pre-ejection periods (LVPEP and RVPEP). These values were
compared with normal values according to the Boston Z-scores [11]. Left ventricular
mass index (LVMI) was calculated using the Devereux formula and indexed by body
surface area [12]. Left ventricular hypertrophy was considered to be present if the LVMI
Z-scores were N+2SD [11].
Systolic function was examined by calculating the shortening fraction (SF). Values
between 28 and 44% were considered normal [13]. To assess diastolic function, we used
conventional Doppler imaging to examine the E/A ratio. The resulting measurements of
the peak early (E) and late (A) transmitral ﬁlling velocities were then compared with
published reference values [14]. In January 2007, to optimize the assessment of diastolic
function, pulsed wave Tissue Doppler Imaging (PWTDI) was added to the study protocol
as an evaluation method. PWTDI velocities from the standard apical four-chamber views
were acquired as described [10] and compared with corresponding measurements in
age and sex-matched healthy controls.
Relative wall thickness (RWT) was calculated as RWT = ((IVSd + LVPWd)/LVIDd).
A cut-off value of 0.42was used to divide left ventricular (LV) hypertrophy into concentric
(RWT N 0.42) and eccentric hypertrophy (RWT b 0.42) [15]. Patients without LV hypertro-
phy were classiﬁed as normal (RWT b 0.42) or concentric remodeling (RWT N 0.42).
2.4. Electrocardiography
Standardized 12 lead electrocardiograms (ECGs) were made using a Mortara ELI 350
ECG machine (Mortara Instrument Inc., Milwaukee, USA.) At regular intervals, we ob-
tained ECGs for all patients in order to determine the PR interval, the QT interval corrected
for heart rate, the LV voltages, and any rhythmor conduction disturbances. TheQT interval
was measured in lead II, V5, or V6. The corrected QT interval was determined by dividing
themeasured QT interval by the square root of the RR interval (Bazett's formula). LV volt-
ages were calculated using the sum of the R wave in lead V6 and the S wave in lead V1.
Pediatric reference values were obtained from Rijnbeek et al.; these consisted of a Dutch
cohort from Rotterdam and were corrected for age and heart rate [16]. Two investigators
examined all ECGs (CvC, IF).
2.5. Statistical analysis
For mitral valve E/A ratio, Z-scores were calculated as the difference between the
measured value and the mean reference value divided by the standard deviation from
the reference value. Z-scores N2 or b−2 were considered abnormal. Measurements of
PWTDI velocities and mitral valve E and A velocities at each patient's last assessment
were compared with corresponding measurements in age and sex-matched healthy con-
trols who have participated in an echocardiographic normal value study of our institute
[17]. Variables were summarized using descriptive statistics comprising median and
range. Differences in cardiac dimensions over time were evaluated using the Wilcoxon
rank signed test. P-values b .05were considered statistically signiﬁcant. Statistical analyses
were performed using SPSS version 21.0.
3. Results
3.1. Patients
Fourteen patients were treated for N12 months and included in this
study; their baseline characteristics are summarized in Table 1. Age atPlease cite this article as: C.I. van Capelle, et al., Cardiac outcome in classic
human acid alpha-glucosidase, Int J Cardiol (2018), https://doi.org/10.101start of treatment ranged from 3 days to 8.3 months (median age
2.7 months). At study end, the duration of ERT ranged from 1.1 to
13.9 years (median 4.8 years). All patients had fully deleterious
variations in the GAA gene, and profound deﬁciency of alpha-
glucosidase activity. The commonest variations were c.2481
+102_2646+31del, which leads to an in-frame deletion of exon
18, and c.del525T, which leads to an unstable messenger with no
GAA-protein production. Together they accounted for 15 of the 24 var-
iations found in the GAA gene. Two patients were cross-reactive immu-
nologic material (CRIM) negative, which implies that the variants on
both alleles did not result in any GAA protein production.
At start of therapy, all patients had concentric LV hypertrophy
(Table 2). Two patients had LV outﬂow-tract obstruction, and two
others had accelerated mid-ventricular velocities of the left ventricle.
Four patients (patients 2, 3, 4 and 12) experienced symptoms of conges-
tive heart failure. At start, ten used cardiac medication (Table 1), at
study end ﬁve still needed medication. Systemic blood pressures and
renal function were within normal limits. All patients were hypotonic
and most showed clearly reduced scores on the Alberta Infant Motor
Scale (Table 1). Two patients were in an end-stage condition of the
disease (patients 2 and 4). Four patients required oxygen via nasal
prong/cannula (patients 4, 7, 8 and 13); oneother patientwas ventilator
dependent (patient 2). During follow-up, four other patients became
ventilator dependent. Later, two of these patients (both CRIM negative)
died, at 4.4 and 4.3 years. Neither patient died due to cardiac complica-
tions. Patient 3 died after a period of unexplained hyperthermia, possi-
bly due to brainstem dysfunction. Patient 5 died due to respiratory
failure during a viral infection.3.2. Echocardiography
3.2.1. LV morphology
At baseline, LVMI was profoundly elevated in all patients (median
LVMI 226 g/m2, range 98 to 599 g/m2; median Z-score 7, range 2.4–
12.4; Table 2). The LVPWd was elevated at baseline in 13 patients.
Fig. 1 shows the effect of ERT on LVMI and LVPWd over time, both
show similar effects during follow-up. In eight patients, LVMI decreased
immediately after start of ERT. In the remaining six patients it continued
to increase for the ﬁrst four weeks (median increase 79.0 g/m2 (range
12.4–149 g/m2)), and then declined. At the last assessment, the median
LVMI was 70.8 g/m2 (range 48.2 to 119.6 g/m2, median; Z-score, 0.3
range−0.9 to +2.4); in 13 patients it had normalized (Fig. 2).
Median time to normalizationwas 30weeks (range 3 to 660weeks).
LVMI also normalized in patient 12, who had had dilated hypertrophic
cardiomyopathy at start. One patient who never reached fully normal
values died at the age of 4.3 years.3.2.2. Cardiac systolic and diastolic function
At baseline, four patients had decreased left ventricular SF
(Table 2). SF normalized during treatment. At baseline diastolic
function of the LV as measured by E/A ratio was normal in all
patients. At follow-up, two patients had abnormalities in diastolic
function: patient 3 showed a decline in diastolic function before
she died; patient 2, who had end-stage disease, had abnormal E/A
ratios in most measurements.3.3. Diastolic function measured by TDI
At last assessment, we obtained TDI values for 10 patients. The
results are shown in Table 3. The early mitral inﬂow velocities (E’)
were signiﬁcantly lower and the tricuspid A’ velocities were signiﬁ-
cantly higher than in healthy age-matched controls. In the patient
group, MV E/E’ ratios were slightly increased.infantile Pompe disease after 13years of treatment with recombinant
6/j.ijcard.2018.07.091
Table 1
Clinical features.
Pt Gender Age at
diagnosis
(months)
Age at
start ERT
(months)
Weight
(kg)/height (cm)
at start ERT
Age at study
end in months
(years)
Survivalb Weight
(kg)/height (cm)
at study end
Mutations CRIM
status
Baseline cardiac
medicationd
Start invasive
ventilation
(years)
AIMS at
baseline
(P-value)
Maximal motor
milestone
1 M 0.7 3.8 7.8/76 171 (14.2) Alive 51/175 c.2481+102_2646+31del
c.1799GNA
+ None − 10 (22) Persistent walker
2 F 3.6 7.2 8.3/73 174 (14.5) Alive 55/165 c.1115ANT
c.525delT
+ Diuretics 0.6a 5 (0) Tetraplegic
3 F 0.6 3.0 5.8/60 51 (4.3) Deceased 18.9/110 c.525delT
c.525delT
− Diuretics 2.2 4 (1) Sitting
4 F 6.2 8.3 5.7/62 174 (14.5) Alive 33.6/146 c.1913GNT
c.1548GNA
+ Diuretics, ACE-inhibitor
and Digoxin
0.9 5 (0) Tetraplegic
5 M 0.2 1.9 4.0/52 53 (4.4) Deceased 16.7/107 c.2741delinsCAG
c.2741delinsCAG
− Diuretics 2.0 6 (25) Walkingc
6 M 0.7 1.2 3.6/52 103 (8.6) Alive 40/132 c.del525T
c.1933GNT
+ Beta-blocker − 3 (1) Persistent walker
7 F 0.2 0.5 4.0/50 98 (8.2) Alive 32/134 c.2481+102_2646+31del
c.2481+102_2646+31del
+ ACE-inhibitor − 4 (36) Persistent walker
8 M 0.1 0.1 3.2/46 69 (5.8) Alive 19.6/113 c.1460TNC
c.1460TNC
+ None 2.7 2 (3) Walkingc
9 M 2.0 2.2 4.8/59 64 (5.3) Alive 21.7/115 c.525delT
c.2481+102_2646+31del
+ None − 7 (12) Bum scoots
10 F 2.3 2.4 6.3/66 52 (4.3) Alive 23.4/114 c.2481+102_2646+31del
c.2481+102_2646+31del
+ Beta-blocker − 1 (0) Persistent walker
11 F 0.1 0.3 4.2/52 27 (2.2) Alive 13/88 c.525delT
c.1933GNA
+ None − 2 (3) Persistent walker
12 F 4.4 4.6 5.8/65 26 (2.2) Alive 13/91 c.2104CNT
c.379_380del
+ Diuretics and ACE-inhibitor − 6 (0) Persistent walker
13 M 3.8 3.8 61/67 24 (2.0) Alive 13.4/88 c.2481+102_2646+31del
c.525delT
+ Diuretics and beta-blocker − 4 (0) Persistent walker
14 M 2.9 3.0 5.4/62 17 (1.4) Alive 10.2/82 c.2104CNT
c.2481+102_2646+31del
+ Diuretics − 7 (5) Pulls to stand
a Invasive ventilation started before start of ERT.
b Two patients died; their deaths were not related to cardiac events.
c Lost the ability to walk after becoming ventilator dependent.
d Baseline cardiac medication. Patients 2, 3, 4 and 12 experienced symptoms of congestive heart failure, in the other patients medication was started as standard treatment for hypertrophic cardiomyopthy.
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During follow-up, we evaluated a total of 118 ambulant ECGs from
14 patients. At baseline, PR interval had been normal in nine patients
and shortened in ﬁve (median PR interval 80 ms, range 60 to 100 ms;
Table 2). At study end, the PR interval was within normal limits in six
patients and was shortened in eight.
At baseline, LV voltages had been substantially increased (median
4.8 mV, range 2.2 to 8.6 mV); after start of ERT they declined (median
3.9 mV, range 1.7 to 6.2 mV). All patients had also had repolarization
disturbances (strain). This normalized in all patients, except in patients
2, 3 and 5, in whom LVMI was slightly increased at last assessment
or who showed increased value(s) of LVMI in the measurement
(s) before the ﬁnal one. Four patients (patient 1, 9, 10 and 13) had an
incomplete right-bundle-branch block.
At baseline, the corrected QT-interval was normal in ten patients
(median: 390ms range 340 to 430ms), and shortened in four (patients
1, 4, 13 and 14). At study end, corrected QT-interval was normal in ten
patients, shortened in three (patients 4, 5 and 11), and increased in
one (patient 2).
Delta waves, suggestive forWolff-Parkinson-White (WPW) pattern,
were found in six patients (patients 2, 4, 6, 7, 9 and10). In the years after
start of therapy, arrhythmias had been documented in three patients
(patients 2, 4 and 5). Holter ECGs were performed in four patients
(patients 2, 4, 7 and 12).Multiple episodes of supraventricular tachycar-
dia (SVT) were documented in patients 2 and 4. Patient 5 had one
episode of SVT, in the days before he died. The tachyarrhythmia were
successfully converted by adenosine; in patient 2, rhythm control was
established by Sotalol, and in patient 4 it was established by Atenolol
and Flecainide. Due to frequent relapses, patient 4 underwent ablation
of three aberrant pathways. In patient 2, the most recent Holter ECG
revealed severe sinus bradycardia (range of 35 bpm to 97 bpm) and
over 6000 pauses were recorded over 24 h, with a maximum duration
of 3.5 s. Due to the patient's poor clinical condition, it was decided not
to implant a pacemaker.4. Discussion
Due to a positive effect of ERT on cardiac hypertrophy,manypatients
with classic-infantile Pompe disease treated with ERT have now sur-
vived far beyond their ﬁrst year of life [5–8,18–20]. Studies particularly
focusing on the long-term consequences on cardiac structure, rhythm
and function have not been performed, which was the reason for this
study.4.1. Effect of ERT on left ventricular mass and systolic function
At start of ERT, all patients in our study had prominent hypertrophic
cardiomyopathy, with LVMIs of up to 599 g/m2 (Z-scores of up
to +12.4). As hypertrophy was already present in patients who
had been diagnosed shortly after birth, it may – as noted by others
[21,22] – have developed during pregnancy. Earlier we found in
untreated patients that the extent of hypertrophy was related to age
[2]. Extraordinary one of our patients had severe dilated cardiomyopathy
as well as hypertrophy.
Our study showed that ERT led to a signiﬁcant effect on LVMI,
LVPWd and systolic function in all patients (Fig. 1). Reduction of LVMI
and LVPWd were seen in previous studies with a shorter follow-up
[8,23,24], new is that this effect is preserved for almost 14 years of
ERT. LVMI normalized in 13 patients. Those in whom it did not fully
normalize (n = 2), or in whom it increased slightly (n = 1), either
died, or were in the end stage of disease at the start of ERT with a very
high baseline LVMI. In none of these patients was cardiac failure the
cause of death.infantile Pompe disease after 13years of treatment with recombinant
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Fig. 1. Left ventricular cardiac dimensions over time. A) LVMI Z-scores B) LVPWd Z-scores C) LVMI raw scores D) LVM raw scores. Each of the 14 patients is represented by a different line.
The dashed grey lines represent the upper and lower limit of normal (Z-score of +2 and−2) and normal value (Z-score of 0).
5C.I. van Capelle et al. / International Journal of Cardiology xxx (2018) xxx–xxxAt study end, systolic LV function was normal in all patients. A study
by Chen et al. limited to 12 months of ERT also showed that LV function
improved [25].
4.2. Effect of ERT on diastolic function
Using conventional echocardiography, we found no diastolic
dysfunction at baseline. However, pseudo-normalization of E/A ratio
cannot be ruled out. As PWTDI appears to be more sensitive than
conventional echocardiography in detecting abnormalities in diastolic
function, we added this measurement to our follow-up protocol.
At the end of the follow-up period, patients had signiﬁcantly lower E’
velocities and a trend to higher E/E’ ratios at the level of the mitral
valve compared to controls. This was also observed by Chen et al. after
one year of ERT [25]. This suggests that patients with Pompe disease
who receive ERT have abnormal relaxation of the left ventricle, and
also increased ﬁlling pressures. However, these data are difﬁcult to
interpret, since, in healthy young children, E’ values and E/E’ ratios
also change signiﬁcantly. In future studies, new imaging techniques
such as speckle tracking might help to detect diastolic dysfunction at
an early stage [26].
4.3. Effect of ERT on ECG parameters and cardiac rhythm
In line with the effect of ERT on LVMI, we found a reduction in LV
voltages. Repolarization disturbances also disappeared. Importantly,
despite treatment with ERT, the short PR and WPW pattern remained
present. At start of ERT, 36% of patients had had a short PR interval;
at the end of the study, 57% did. At end of study, six patients had a
WPW pattern.
A short PR interval is often found in patients with classic infantile
Pompe disease [27,28], it is also found in other storage diseases affecting
the heart such as Fabry disease and Danon disease, and in patients with
PRKAG2 mutations [29,30].Please cite this article as: C.I. van Capelle, et al., Cardiac outcome in classic
human acid alpha-glucosidase, Int J Cardiol (2018), https://doi.org/10.101The mechanism underlying this short PR interval is not completely
understood; an interesting hypothesis was raised in 1982 by Bharati
et al., who correlated electrophysiological abnormalities with patholog-
ical postmortem ﬁndings in the conduction systemof untreated patients
with classic-infantile Pompe disease. They foundmarked glycogen inﬁl-
tration and vacuolization and an increase in cell size of the Purkinje cells
and suggesting that the short PR interval reﬂected an enhancement of
conduction caused by the deposition of glycogen [31]. The electrophys-
iological ﬁnding that the atrium-His interval was shortened and the
His-ventricular interval was normal, while enlarged cells ﬁlled with gly-
cogen were found in all parts of the conduction system including the
bundle of His, challenges this hypothesis. Another theory was proposed
by Arad et al. [32], who studied a mouse model with a human PRKAG2
mutation, a disease that leads to glycogen accumulation in the
cytoplasm of cardiomyocytes. They observed that the annulus ﬁbrosis
was disrupted by glycogen-ﬁlled cardiomyocytes, allowing atrioventric-
ular activation by bypassing the AV node. This disruption might also
explain the short PR interval and the WPW pattern, and the fact that
patients were prone to developing SVTs or severe bradycardia.
Various publications report that arrhythmias, including fatal ar-
rhythmia such as SVT and ventricular ﬁbrillation (VF), may occur in
patients with classic-infantile Pompe disease [9,28,33,34]. Three of our
patients developed spontaneous periods of SVTs, which required
medical intervention. These ﬁndings may relate to the observed WPW
pattern. While our patients with recurrent SVTs were already severely
affected at start of therapy, we cannot rule out that patients who
respond well may also develop SVTs or other rhythm disturbances.
We therefore advise regular monitoring of all patients receiving
long-term ERT.
5. Limitations of the study
This study has several limitations. Due to the rarity and severity of
the disease, research in Pompe disease is restricted to cohort studies
with relatively small sample sizes.infantile Pompe disease after 13years of treatment with recombinant
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Fig. 2. Echocardiographic parasternal long axis view of patient 9. Echocardiographic
parasternal long axis view of patient 9 at A) baseline and B) after 5 years of treatment.
Note the major difference in both septal and posterior wall thickness.
6 C.I. van Capelle et al. / International Journal of Cardiology xxx (2018) xxx–xxxIn addition, increasing insight into the treatment of Pompe disease
has led to adaptations in dosage regimens speciﬁcally because of
skeletal muscle weakness. With respect to cardiac hypertrophy we
observed a good response in all patients in our group regardless of the
dose. This does not rule out that a higher dose may have had additional
beneﬁt in some patients. For several reasons some patients did notTable 3
Pulsed Doppler and Pulsed-wave Tissue Doppler velocities at ﬁnal assessment.
Patients
n Median
Age (years) 10 5.0
Pulsed Doppler velocities
Mitral valve E velocity (cm/s) 10 98.8
Mitral valve A velocity (cm/s) 10 58.2
Mitral valve E/A ratio 10 1.7
Pulsed-wave tissue Doppler velocities
Mitral valve lateral E’ velocity (cm/s) 10 14.2
Mitral valve lateral A’ velocity (cm/s) 10 5.5
Mitral valve E/E' ratio 10 6.9
Tricuspid valve lateral E’ velocity (cm/s) 8 12.7
Tricuspid valve lateral A’ velocity (cm/s) 9 9.7
Statistically signiﬁcant values are marked in bold/italics.
a Institutional reference values.
b Wilcoxon rank singed test.
Please cite this article as: C.I. van Capelle, et al., Cardiac outcome in classic
human acid alpha-glucosidase, Int J Cardiol (2018), https://doi.org/10.101receive ERT, this may have inﬂuenced our data in part, it should be
noted however that patients included in the study and treated with
ERT represented the entire spectrum of disease severity of classic infan-
tile Pompe disease. Because PWTDI was not yet available at the start of
the study, our follow-up of diastolic function is limited and should be
interpreted with caution.
6. Conclusion
This study shows that ERT has a signiﬁcant effect on cardiac dimen-
sions, whichwasmaintained for almost 14 years. During the ﬁrst weeks
of treatment, before it starts to decline and eventually reaches normal
values, LVMImay continue to increase. The time to normalization differs
between patients: in some patients LVMI remained slightly elevated or
showed a secondary increase. Two patients died, but not because of
cardiac failure. In most patients, the effect decrease in LVMI was
reﬂected in reductions of LV voltages and the disappearance of repolar-
ization disturbances. Patients remained at risk of rhythm disturbances.
At study end, 57% of patients had a short PR interval, 43% had a WPW
pattern and 21% had SVTs, indicating that regulatory cardiacmonitoring
of patients remains warranted.
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74.8–127.8 14 100.4 78.8–120.9 1.0
31.8–81.1 14 54.9 36.5–67.1 .3
1.0–4.0 14 1.8 1.4–3.1 .2
7.9–17.9 13 18.7 16.5–24.0 .00
3.2–7.0 13 5.3 3.8–12.5 .7
5.3–11.5 13 5.2 3.9–6.6 .01
10.7–19.9 13 12.9 10.6–15.2 .9
3.6–13.4 13 6.8 4.9–9.8 .02
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